Related references
Note: Only part of the references are listed.Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Thorsten Simon et al.
BMC CANCER (2011)
Comparison of 123I-Metaiodobenzylguanidine (MIBG) and 131I-MIBG Semi-Quantitative Scores in Predicting Survival in Patients With Stage 4 Neuroblastoma: A Report From the Children's Oncology Group
Arlene Naranjo et al.
PEDIATRIC BLOOD & CANCER (2011)
Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project
Herve J. Brisse et al.
RADIOLOGY (2011)
Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
K. K. Matthay et al.
BRITISH JOURNAL OF CANCER (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastorna >1 year of age on a high-risk treatment protocol:: Results of the German Neuroblastoma Trial NB97
Matthias Schmidt et al.
EUROPEAN JOURNAL OF CANCER (2008)
Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97
Barbara Hero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
Julia A. Messina et al.
PEDIATRIC BLOOD & CANCER (2006)
Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease
Thorsten Simon et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2006)
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
F Berthold et al.
LANCET ONCOLOGY (2005)
Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma
HM Katzenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
T Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age
F Berthold et al.
CANCER LETTERS (2003)
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Guidelines for radioiodinated MIBG scintigraphy in children
P Olivier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
